[go: up one dir, main page]

BG106406A - Pyrimidine-2,4,6-trione metalloproteinase inhibitors - Google Patents

Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Info

Publication number
BG106406A
BG106406A BG06406A BG10640602A BG106406A BG 106406 A BG106406 A BG 106406A BG 06406 A BG06406 A BG 06406A BG 10640602 A BG10640602 A BG 10640602A BG 106406 A BG106406 A BG 106406A
Authority
BG
Bulgaria
Prior art keywords
pyrimidine
metalloproteinase inhibitors
trione metalloproteinase
trione
disorders
Prior art date
Application number
BG06406A
Other languages
Bulgarian (bg)
English (en)
Inventor
Julian Blagg
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106406A publication Critical patent/BG106406A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG06406A 1999-08-12 2002-02-12 Pyrimidine-2,4,6-trione metalloproteinase inhibitors BG106406A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14854799P 1999-08-12 1999-08-12
PCT/IB2000/001090 WO2001012611A1 (en) 1999-08-12 2000-08-03 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BG106406A true BG106406A (en) 2002-09-30

Family

ID=22526231

Family Applications (1)

Application Number Title Priority Date Filing Date
BG06406A BG106406A (en) 1999-08-12 2002-02-12 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Country Status (41)

Country Link
US (1) US6579982B1 (xx)
EP (1) EP1202974B1 (xx)
JP (1) JP2003507371A (xx)
KR (2) KR20040073608A (xx)
CN (1) CN1156454C (xx)
AR (1) AR025091A1 (xx)
AT (1) ATE309224T1 (xx)
AU (1) AU773751B2 (xx)
BG (1) BG106406A (xx)
BR (1) BR0013081A (xx)
CA (1) CA2381551A1 (xx)
CO (1) CO5180629A1 (xx)
CR (1) CR6565A (xx)
CZ (1) CZ2002355A3 (xx)
DE (1) DE60023903D1 (xx)
EA (1) EA004680B1 (xx)
EC (1) ECSP003610A (xx)
EE (1) EE200200069A (xx)
GE (1) GEP20053424B (xx)
GT (1) GT200000137A (xx)
HK (1) HK1045995B (xx)
HN (1) HN2000000137A (xx)
HR (1) HRP20020129A2 (xx)
HU (1) HUP0202501A3 (xx)
IL (1) IL148035A0 (xx)
IS (1) IS6248A (xx)
MA (1) MA26812A1 (xx)
MX (1) MXPA02001561A (xx)
NO (1) NO20020662L (xx)
NZ (1) NZ516562A (xx)
OA (1) OA12000A (xx)
PA (1) PA8498701A1 (xx)
PE (1) PE20010491A1 (xx)
PL (1) PL353871A1 (xx)
SK (1) SK1652002A3 (xx)
TN (1) TNSN00169A1 (xx)
TR (1) TR200200381T2 (xx)
UY (1) UY26285A1 (xx)
WO (1) WO2001012611A1 (xx)
YU (1) YU6602A (xx)
ZA (1) ZA200201070B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA03003735A (es) * 2000-10-26 2003-07-28 Pfizer Prod Inc Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas.
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CZ20031069A3 (cs) * 2000-10-26 2004-05-12 Pfizeráproductsáinc Pyrimidin@@Ź@Ź@@trionové inhibitory metaloproteinasy
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
WO2002064578A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Benzo thiadiazine matrix metalloproteinase inhibitors
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2003090751A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
EP1501834B1 (en) * 2002-04-26 2005-09-07 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DE60302150D1 (en) * 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
JP2006504665A (ja) 2002-08-13 2006-02-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
BR0313384A (pt) 2002-08-13 2005-07-12 Warner Lambert Co Derivados de cromona como inibidores de metaloproteinases de matriz
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US20150366275A1 (en) * 2014-06-19 2015-12-24 Gyula Cserfoi Wearable Signaling Device
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334253A (en) * 1996-08-28 2000-11-24 Procter & Gamble N-hydroxy 1-[(4-methoxyphenyl)sulfonyl]-4-benzyloxycarbonyl-piperazine 2-carboxamide and derivatives thereof for treating musculoskeletal disease or cachexia
BR9810450A (pt) * 1997-06-21 2000-09-05 Roche Diagnostics Gmbh Derivados de ácido barbitúrico com atividade antimetastática e antitumor

Also Published As

Publication number Publication date
ECSP003610A (es) 2002-03-25
HK1045995B (zh) 2004-12-31
EP1202974B1 (en) 2005-11-09
EP1202974A1 (en) 2002-05-08
TNSN00169A1 (fr) 2005-11-10
HK1045995A1 (en) 2002-12-20
ZA200201070B (en) 2003-04-30
WO2001012611A1 (en) 2001-02-22
MA26812A1 (fr) 2004-12-20
UY26285A1 (es) 2001-03-16
CR6565A (es) 2004-02-23
PL353871A1 (en) 2003-12-01
IL148035A0 (en) 2002-09-12
CA2381551A1 (en) 2001-02-22
HUP0202501A3 (en) 2003-02-28
CN1368963A (zh) 2002-09-11
CZ2002355A3 (cs) 2002-07-17
SK1652002A3 (en) 2002-09-10
YU6602A (sh) 2004-11-25
BR0013081A (pt) 2002-04-23
AR025091A1 (es) 2002-11-06
PA8498701A1 (es) 2002-08-26
EA004680B1 (ru) 2004-06-24
NO20020662L (no) 2002-04-09
NZ516562A (en) 2003-06-30
AU773751B2 (en) 2004-06-03
NO20020662D0 (no) 2002-02-11
PE20010491A1 (es) 2001-04-25
HUP0202501A2 (hu) 2002-12-28
ATE309224T1 (de) 2005-11-15
TR200200381T2 (tr) 2002-05-21
CO5180629A1 (es) 2002-07-30
AU6010500A (en) 2001-03-13
OA12000A (en) 2006-04-18
HN2000000137A (es) 2001-02-02
KR20020047119A (ko) 2002-06-21
EE200200069A (et) 2003-04-15
GT200000137A (es) 2002-02-01
DE60023903D1 (de) 2005-12-15
JP2003507371A (ja) 2003-02-25
CN1156454C (zh) 2004-07-07
HRP20020129A2 (en) 2004-04-30
IS6248A (is) 2002-01-25
US6579982B1 (en) 2003-06-17
EA200200058A1 (ru) 2002-06-27
MXPA02001561A (es) 2002-07-02
KR20040073608A (ko) 2004-08-19
GEP20053424B (en) 2005-01-25

Similar Documents

Publication Publication Date Title
BG106406A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2002034726A3 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
AP2001002318A0 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2003091259A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
MY121294A (en) Novel hexanoic acid derivatives.
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
BG105880A (en) Compounds useful as anti-inflammatory agents
YU39101A (sh) Aromatična hetrerociklična jedinjenja kao antiinflamatorni agensi
BG106013A (en) New compounds and compositions as protease inhibitors
BG106242A (en) Metalloprotease inhibitors
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
AU1182702A (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
UY27772A1 (es) Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
MY127819A (en) Optically pure camptothecin analogues
MY136138A (en) Hexacyclic compounds
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.